SenesTech, Inc.

As of March 16, 2023, SenesTech, Inc. is classified as risky due to its negative P/E ratio and poor returns on capital and equity, indicating it is overvalued compared to peers, despite a recent 41.69% year-to-date return, which is overshadowed by a long-term decline of 99.55% over three years.

As of March 16, 2023, SenesTech, Inc. is rated "risky" and considered overvalued due to negative financial ratios, including a Price to Book Value of 1.74 and troubling returns, despite a recent monthly gain of 47.33%, following a significant annual decline of 34.53%.

As of June 10, 2025, the technical trend is mildly bullish, supported by positive MACD and KST indicators, although caution is warranted due to mildly bearish daily moving averages and mixed signals from Bollinger Bands.

As of March 2022, the management team of SenesTech, Inc. includes Dr. Jamie Morrison (Independent Chairman), Mr. Kenneth Siegel (CEO), and several independent directors: Ms. Delphine Chiavarini, Mr. Marc Dumont, Mr. Phil Grandinetti, Ms. K. Kavanagh, and Mr. Jake Leach. The team features a blend of executive leadership and independent oversight.

SenesTech, Inc. is a biotechnology company focused on managing animal pest populations through fertility control, operating in the micro-cap Chemicals & Petrochemicals industry. As of March 2025, it reported net sales of $0 million and a net loss of $2 million, with a market cap of $6.70 million.

As of Jun 18, SenesTech, Inc. has a market capitalization of 6.70 million and reported net sales of 1.92 million with a net profit of -6.01 million over the last four quarters.